Parkinson's disease is fundamentally characterized by a pathological imbalance between neurotransmitters, specifically defined as dopaminergic depletion and relative cholinergic excess within the substantia nigra due to neuronal degeneration. The therapeutic principle relies on pharmacological intervention designed exclusively through two distinct theoretical mechanisms: restoring central dopamine levels or reducing peripheral acetylcholine activity to normalize the inverse neurochemical ratio. This framework operates within clinical neuropharmacology, where drug efficacy is determined by their specific targets in dopaminergic synthesis pathways, receptor agonism sites, re-uptake inhibition channels, and muscarinic antagonistic actions.
Parkinson's disease is fundamentally characterized by a pathological imbalance between neurotransmitters, specifically defined as dopaminergic depletion and relative cholinergic excess within the sub…